VOLITIONRX LTD — Director's Dealing 2024

Jan 26, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2024-01-24-05:00

Reporting Person: Reynolds Cameron John (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-24-05:00	Common Stock	A	50150	—	Acquired	1754668	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1007718	Indirect
Common Stock	34076	Indirect

Footnotes

F1: On September 28, 2023, the reporting person was awarded 118,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 50,150 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 16,717 units, 16,717 units, and 16,716 units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

F2: The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.